THC.CSETHCBF - OTCTFHD.F VANCOUVER, BC, March 10, 2021 /PRNewswire/ THC BioMed Intl Ltd. ("THC BioMed" or the "Company") is pleased to announce that it has shipped its THC Kiss Gummies
THC BioMed Receives Purchase Order for THC Kiss Gummies from the Province of B.C.
THC BioMed or the
BC Cannabis Stores.
THC is also pleased to advise it has received a reorder for its THC Kiss Gummies from its distributor in Saskatchewan, which has reported brisk sales of THC Kiss Gummies.
THC Kiss Gummies are infused with our propriety THC Kiss cannabis extract. Each package of THC Kiss Gummies contains 4 gummies with a total of 10 mg of THC. We are pleased to launch our strawberry flavoured THC Kiss Gummies in B.C. We have many more flavours in development. THC is well positioned to cater to a mature and evolving cannabis market. Our beverage and edible products are in a league of their own, allowing us to capture brand recognition. Our invention of our own proprietary extraction system gives us a competitive advantage. We look forward to increasing and sustaining our market share with innovative products that deliver, commented John Miller, CEO and President of THC Bio
Compass Launches Center Of Excellence
Compass Pathways (NASDAQ:CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland.
This “clinic model” will study and build the best therapy models for psychedelics treatment and work as a site for clinical trials as well as a laboratory for innovation. It will also explore research around COMP360, Compass’ psilocybin drug candidate.
Scott Aaronson MD, Director of Clinical Research at Sheppard Pratt, will lead the center.
“Sheppard Pratt has a long history of excellence in clinical service delivery and commitment to its community of patients,” Compass Pathways CEO George Goldsmith said. “Our Centers of Excellence, beginning with this centre led by the distinguished team at Sheppard Pratt, will help to accelerate our combined work so that we can bring evidence-based innovation, on a large scale, to the people who need
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
News provided by
Share this article
Share this article
The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM
, Mind Cure s digital therapeutics platform.
VANCOUVER, BC, Jan. 12, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( Mind Cure or the
LOI ) for strategic investment and commercial cooperation with
ATMA Journey Centers Inc. (
ATMA ), a Calgary-based organization. ATMA is the first commercial treatment center in Canada to announce providing psychedelic-assisted therapy for a section 56 exempt patient. The LOI is intended to help Mind Cure secure an equity position within ATMA, empowering the Company with access to a global release strategy for